103 related articles for article (PubMed ID: 16611148)
1. Characterization and inhibition of SARS-coronavirus main protease.
Liang PH
Curr Top Med Chem; 2006; 6(4):361-76. PubMed ID: 16611148
[TBL] [Abstract][Full Text] [Related]
2. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
Pillaiyar T; Manickam M; Namasivayam V; Hayashi Y; Jung SH
J Med Chem; 2016 Jul; 59(14):6595-628. PubMed ID: 26878082
[TBL] [Abstract][Full Text] [Related]
3. Mutational and inhibitive analysis of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer-based assays.
Kuang WF; Chow LP; Wu MH; Hwang LH
Biochem Biophys Res Commun; 2005 Jun; 331(4):1554-9. PubMed ID: 15883050
[TBL] [Abstract][Full Text] [Related]
4. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery.
Ramajayam R; Tan KP; Liang PH
Biochem Soc Trans; 2011 Oct; 39(5):1371-5. PubMed ID: 21936817
[TBL] [Abstract][Full Text] [Related]
5. Recent developments on coronavirus main protease/3C like protease inhibitors.
Zhao Q; Weber E; Yang H
Recent Pat Antiinfect Drug Discov; 2013 Aug; 8(2):150-6. PubMed ID: 23879823
[TBL] [Abstract][Full Text] [Related]
6. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors.
Shi J; Wei Z; Song J
J Biol Chem; 2004 Jun; 279(23):24765-73. PubMed ID: 15037623
[TBL] [Abstract][Full Text] [Related]
7. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate.
Kuo CJ; Chi YH; Hsu JT; Liang PH
Biochem Biophys Res Commun; 2004 Jun; 318(4):862-7. PubMed ID: 15147951
[TBL] [Abstract][Full Text] [Related]
8. Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.
Liu YC; Huang V; Chao TC; Hsiao CD; Lin A; Chang MF; Chow LP
Biochem Biophys Res Commun; 2005 Jul; 333(1):194-9. PubMed ID: 15950190
[TBL] [Abstract][Full Text] [Related]
9. Residues on the dimer interface of SARS coronavirus 3C-like protease: dimer stability characterization and enzyme catalytic activity analysis.
Chen S; Zhang J; Hu T; Chen K; Jiang H; Shen X
J Biochem; 2008 Apr; 143(4):525-36. PubMed ID: 18182387
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.
Liu W; Zhu HM; Niu GJ; Shi EZ; Chen J; Sun B; Chen WQ; Zhou HG; Yang C
Bioorg Med Chem; 2014 Jan; 22(1):292-302. PubMed ID: 24316352
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus.
Sun H; Luo H; Yu C; Sun T; Chen J; Peng S; Qin J; Shen J; Yang Y; Xie Y; Chen K; Wang Y; Shen X; Jiang H
Protein Expr Purif; 2003 Dec; 32(2):302-8. PubMed ID: 14965777
[TBL] [Abstract][Full Text] [Related]
12. Crystal Structure of Feline Infectious Peritonitis Virus Main Protease in Complex with Synergetic Dual Inhibitors.
Wang F; Chen C; Liu X; Yang K; Xu X; Yang H
J Virol; 2016 Feb; 90(4):1910-7. PubMed ID: 26656689
[TBL] [Abstract][Full Text] [Related]
13. Ferrocenoyl-substituted quinolinone and coumarin as organometallic inhibitors of SARS-CoV-2 3CLpro main protease.
Graf D; Farn N; Klopf J; Hojjati M; Schatzschneider U
Metallomics; 2023 May; 15(5):. PubMed ID: 37070961
[TBL] [Abstract][Full Text] [Related]
14. Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase.
Liu Z; Huang C; Fan K; Wei P; Chen H; Liu S; Pei J; Shi L; Li B; Yang K; Liu Y; Lai L
J Chem Inf Model; 2005; 45(1):10-17. PubMed ID: 15667124
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2.
Ferreira JC; Rabeh WM
Sci Rep; 2020 Dec; 10(1):22200. PubMed ID: 33335206
[TBL] [Abstract][Full Text] [Related]
16. Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors.
Wang HM; Liang PH
Expert Opin Ther Pat; 2010 Jan; 20(1):59-71. PubMed ID: 20021285
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.
Zhang J; Pettersson HI; Huitema C; Niu C; Yin J; James MN; Eltis LD; Vederas JC
J Med Chem; 2007 Apr; 50(8):1850-64. PubMed ID: 17381079
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors.
Akaji K; Konno H; Mitsui H; Teruya K; Shimamoto Y; Hattori Y; Ozaki T; Kusunoki M; Sanjoh A
J Med Chem; 2011 Dec; 54(23):7962-73. PubMed ID: 22014094
[TBL] [Abstract][Full Text] [Related]
19. Structural and mechanistic aspects of 3C proteases from the Picornavirus family.
Arad D; Kreisberg R; Shokhen M
J Chem Inf Comput Sci; 1993; 33(3):345-9. PubMed ID: 8320292
[TBL] [Abstract][Full Text] [Related]
20. Computational approaches for the discovery of cysteine protease inhibitors against malaria and SARS.
Shah F; Mukherjee P; Desai P; Avery M
Curr Comput Aided Drug Des; 2010 Mar; 6(1):1-23. PubMed ID: 20370692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
